Shots:
- Shionogi to acquire a newly established company that will be created by Tanabe Pharma to hold the rights to Radicava ORS (edaravone) & IV Radicava
- As per the deal, Tanabe Pharma will establish a new entity, & Shionogi will acquire 100% of its shares, with Tanabe’s US Radicava business company becoming a wholly owned subsidiary of Shionogi
- Under the terms, Shionogi will pay Tanabe Pharma a $2.5B lump sum, with additional royalties on future sales payable under certain conditions
Ref: Businesswire | Image: Shionogi & Tanabe Pharma |Press Release
Related News: Shionogi Reports the US FDA’s Acceptance of Ensitrelvir Post-Exposure COVID-19 Prevention
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
